News Sentiment

RANI sentiment intelligence

Rani Therapeutics Holdings Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

84/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-10.9% over one week, -9.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Rani Therapeutics Tries To Turn Biologic Shots Into Pills

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 84/100 classification
One-week reaction -10.9% Price reacting lower
Trend fit Trend inactive -9.6% over four weeks
Fair value -67.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 42
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 10
simplywall.st 6
TradingView 5
GlobeNewswire 4
Investing.com 2
Finimize 1
Quiver Quantitative 1

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 14
Analyst action 3
Deals and strategy 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Investing.com Direct company coverage

Rani Therapeutics reports positive Phase 1 data for oral obesity drug

Rani Therapeutics announced positive initial data from its Phase 1 study of RT-114, an oral capsule for obesity treatment, showing systemic exposure greater than 150% relative to subcutaneous injection with mild, transient side effects. The company plans to expand the Phase 1a st

Tone
Positive 66/100
Event
Market update
Published
15 Jul 2026 16:10
Source
Investing.com
Stock Titan Direct company coverage

Rani’s oral obesity treatment shows 150%+ exposure vs. injection

Rani Therapeutics reported positive initial Phase 1a data for its oral obesity treatment, RT-114, which demonstrated bioavailability exceeding 150% compared to a matched subcutaneous injection of PG-102. The study in 30 healthy volunteers showed no serious adverse events, with mi

Tone
Positive 91/100
Event
Market update
Published
15 Jul 2026 12:10
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (RANI) CFO Nicholas Maestas files initial Form 3 ownership

Rani Therapeutics Holdings, Inc. CFO Nicholas Maestas filed his initial Form 3, an ownership report, on July 8, 2026. This filing serves as a baseline disclosure of his status as a reporting officer

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

New Rani Therapeutics (NASDAQ: RANI) CFO granted options, 2026 inducement plan

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) has appointed Nicholas M. Maestas as its new Chief Financial Officer, effective June 29, 2026. Maestas will receive a $500,000 annual base salary, a target bonus of 75% of his base salary, and a non-qualified option to purchase 2,00

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 09:40
Source
Stock Titan
Market source Direct company coverage

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

Rani Therapeutics Holdings, Inc. has announced the appointment of Nicholas Maestas as their new Chief Financial Officer, effective immediately. Maestas brings over 10 years of financial leadership experience in clinical-stage biotechnology, having previously held roles at Tempest

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 18:39
Source
Market source
TradingView Direct company coverage

Rani Therapeutics Holdings, Inc. Class A Actuals & Estimates (NASDAQ:RANI)

This article provides an overview of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, earnings estimates, and revenue figures, noting the company's next earning

Tone
Negative 40/100
Event
Earnings
Published
26 Jun 2026 06:40
Source
TradingView
Stock Titan Direct company coverage

RANI SEC Filings - Rani Therapeutics Holdings, Inc. 10-K, 10-Q, 8-K Forms

This page provides a comprehensive overview of Rani Therapeutics Holdings, Inc. (RANI) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events. It details the company's regulatory record as a clinical-stage biotherapeutics firm developing oral

Tone
Negative 39/100
Event
Earnings
Published
16 Jun 2026 08:40
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Rani Therapeutics Holdings, Inc. Insider Trading Activity

Rani Therapeutics Holdings, Inc. reported an insider trading activity where Chief Executive Officer Imran Talat received a grant of stock options covering 3,800,000 shares of Class A Common Stock. These options have an exercise price of $0.875 per share and vest over four years,

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (RANI) grants CBO 805,500 stock options

Rani Therapeutics Holdings, Inc. (RANI) reported that Chief Business Officer Kate McKinley was granted 805,500 stock options for Class A Common Stock. These options have an exercise price of $0.875 per share and expire on June 2, 2036. The shares will vest monthly over four years

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (NASDAQ: RANI) CTO awarded 805,500 stock options

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) reported that its Chief Technical Officer, Alireza Javadi, was granted 805,500 stock options. These options have an exercise price of $0.875 per share and will vest monthly over four years, starting April 1, 2026, contingent on cont

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 22:39
Source
Stock Titan
Stock Titan Direct company coverage

Imran Mir A of Rani Therapeutics (NASDAQ: RANI) receives 123,600 stock options

Imran Mir A, a director and ten percent owner of Rani Therapeutics (NASDAQ: RANI), was granted 123,600 stock options. These options have an exercise price of $0.9515 per share and are set to expire on May 27, 2036. The stock options will vest in full on the first anniversary of t

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (NASDAQ: RANI) director receives stock options on 123,600 shares

Rani Therapeutics Holdings director Lisa Ann Rometty was granted stock options for 123,600 Class A common stock shares. These options have an exercise price of $0.9515 per share and expire on May 27, 2036. The options will fully vest on May 28, 2027, one year from the grant date,

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Director Abraham Bassan receives 123,600 Rani (RANI) stock options

Rani Therapeutics Holdings director Abraham Bassan was granted 123,600 stock options for Class A Common Stock with an exercise price of $0.9515 per share. These options represent his entire reported derivative holdings and will vest in full on the first anniversary of the grant d

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (RANI) director granted 123,600 options at $0.9515 exercise price

Rani Therapeutics director Bailey Vasudev Jaiprakash was granted 123,600 stock options at an exercise price of $0.9515 per share on May 28, 2026. These options vest fully on the first anniversary of the grant date, subject to continuous service, or earlier upon the next annual st

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Director at Rani Therapeutics (RANI) receives 123,600 stock options as compensation award

Rani Therapeutics Holdings director Jean Luc Butel was granted 123,600 stock options as a compensation award, not through open market purchase, with an exercise price of $0.9515 per share and an expiration date of May 27, 2036. The options vest in full on the first anniversary of

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (RANI) director receives 123,600 stock options at $0.9515 strike

Rani Therapeutics Holdings director Dennis A. Ausiello was granted 123,600 stock options for Class A common stock, with an exercise price of $0.9515 per share, expiring on May 27, 2036. This compensation-related award vests fully on the first anniversary of the grant date, or ear

Tone
Neutral 50/100
Event
Market update
Published
01 Jun 2026 19:39
Source
Stock Titan
The Globe and Mail Direct company coverage

Rani Therapeutics Announces $20 Million Equity Financing

Rani Therapeutics Holdings has announced a $20 million equity financing through the sale of Class A common stock and pre-funded warrants to institutional investors. The offering, expected to close around May 27, 2026, aims to provide funding flexibility for the biopharmaceutical

Tone
Neutral 50/100
Event
Market update
Published
31 May 2026 00:39
Source
The Globe and Mail
Finviz Direct company coverage

RANI - Rani Therapeutics Holdings Inc Stock Price and Quote

This article provides a detailed stock quote and financial data for Rani Therapeutics Holdings Inc (RANI), including its current stock price, financial metrics, analyst ratings, and a chronological list of recent news and corporate events. It highlights the company's executive te

Tone
Neutral 50/100
Event
Analyst action
Published
29 May 2026 16:13
Source
Finviz
Stock Titan Direct company coverage

Rani Therapeutics (RANI) stockholders elect directors and ratify 2026 auditor

Rani Therapeutics Holdings, Inc. (RANI) held its annual stockholder meeting on May 28, 2026. Stockholders elected all seven nominated directors, including Talat Imran and Mir Imran, to serve until the 2027 annual meeting. They also ratified the appointment of CBIZ CPAs P.C. as th

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 03:08
Source
Stock Titan
Stock Titan Direct company coverage

Akkaraju funds lift Rani Therapeutics (RANI) beneficial stake to 9.99%

Samsara BioCapital funds and Dr. Srinivas Akkaraju have increased their beneficial ownership in Rani Therapeutics Holdings (RANI) to 9.99% following a registered direct offering in May 2026. Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. jointly purchased 1,869,159 s

Tone
Neutral 50/100
Event
Deals and strategy
Published
28 May 2026 21:39
Source
Stock Titan
Stock Titan Direct company coverage

Rani Therapeutics (RANI) raises ~$19.99M via Class A shares and pre-funded warrants

Rani Therapeutics is conducting a registered direct offering to raise approximately $19.99 million in gross proceeds by offering 12.48 million shares of Class A common stock and pre-funded warrants to purchase 6.21 million shares at $1.07 per share. The estimated net proceeds of

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 10:40
Source
Stock Titan